N
Nexstim
Nexstim is a medical device company developing “NBS”–a noninvasive, image-guided TMS for brain diagnostics and therapy.
About Nexstim
Nexstim Plc is a medical technology company specializing in non-invasive brain stimulation (TMS) technology. The company operates primarily in the healthcare sector, serving neurosurgeons and medical professionals who require precise and reliable brain imaging and stimulation solutions. Nexstim's core product is its FDA-cleared TMS technology, which uses advanced 3D imaging to accurately target the electric field (E field) in the brain, providing drug-free therapy for various neurological conditions. The technology is based on decades of scientific research and is designed to offer unmatched accuracy and precision, making it a valuable tool for neurosurgeons and clinicians.
Nexstim generates revenue through the sale of its TMS systems, as well as through service contracts and system upgrades. The company has a strong presence in Europe, with recent orders from Germany and Sweden, and is expanding its market reach globally. Nexstim's business model focuses on continuous innovation and improvement of its technology to meet the evolving needs of the medical community.
The company also engages in research and development to explore new applications for its TMS technology, including risk stratification for patients with functionally eloquent tumors. Nexstim's management team, led by CEO Mikko Karvinen and CFO Joonas Juokslahti, is committed to driving growth and enhancing shareholder value through strategic initiatives and operational excellence.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2000
- Headquarters
- Helsinki, Finland
- Listing
- IPO 2014
- Employees
- 59
- Open positions
- None listed
- Dealroom signal
- 78.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Trading, Publishing, Biotechnology, Retirement, Neurology, Health Diagnostics, Nordic Rising Star 2022, Hard Tech
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | May 2026 | $4.2M | — | Brainlab · Eiffel Investment Group | ↗ |
| POST IPO CONVERTIBLE✓Other financing | Jun 2024 | $825K | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Nexstim is 6.3K monthly website visits, up 28.6% over the last three months. Nexstim's team grew 7.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
HealthCap
Tesi
EQT Life Sciences
Lundbeckfonden
Lundbeckfonden Ventures
Capricorn Partners
Series B and later2 investors entered at this stage
Brainlab
Eiffel Investment Group
Other known investors2 additional known investors
Negma Group
Quest for Growth
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nexstim on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nexstim’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.